A Study to Evaluate the Safety and Tolerability of Arbaclofen Placarbil (XP19986) in Subjects With Acute Back Spasms
Public ClinicalTrials.gov record NCT00817986. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Tolerability of XP19986 in Subjects With Acute Back Spasms
Study identification
- NCT ID
- NCT00817986
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- XenoPort, Inc.
- Industry
- Enrollment
- 161 participants
Conditions and interventions
Conditions
Interventions
- Arbaclofen placarbil, 20 mg Drug
- Placebo Drug
- Arbaclofen placarbil, 30 mg Drug
- Arbaclofen placarbil, 40 mg Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 65 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 30, 2008
- Primary completion
- Jun 30, 2009
- Completion
- Jun 30, 2009
- Last update posted
- Feb 20, 2021
2008 – 2009
United States locations
- U.S. sites
- 20
- U.S. states
- 13
- U.S. cities
- 19
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | Litchfield Park | Arizona | 85340 | — |
| Not listed | Anaheim | California | 92084 | — |
| Not listed | Anaheim | California | 92801 | — |
| Not listed | San Diego | California | 92128 | — |
| Not listed | Vista | California | 92083 | — |
| Not listed | Fort Lauderdale | Florida | 33306 | — |
| Not listed | Miami | Florida | 33143 | — |
| Not listed | Atlanta | Georgia | 30308 | — |
| Not listed | Overland Park | Kansas | 66211 | — |
| Not listed | Erlanger | Kentucky | 41018 | — |
| Not listed | Traverse City | Michigan | 49684 | — |
| Not listed | Brick | New Jersey | 07732 | — |
| Not listed | Raleigh | North Carolina | 27612 | — |
| Not listed | Winston-Salem | North Carolina | 27103 | — |
| Not listed | Oklahoma City | Oklahoma | 73122 | — |
| Not listed | Anderson | South Carolina | 29621 | — |
| Not listed | Dallas | Texas | 75234 | — |
| Not listed | Houston | Texas | 77074 | — |
| Not listed | San Antonio | Texas | 78215 | — |
| Not listed | Salt Lake City | Utah | 84106 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00817986, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 20, 2021 · Synced Jul 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00817986 live on ClinicalTrials.gov.